Understanding Factors Contributing to Student Mortality: A Comprehensive Analysis
Student mortality is a multifaceted issue influenced by various factors ranging from mental health challenges to disparities in healthcare access and treatment. This article delves into these intricate elements, providing a comprehensive overview of the potential causes contributing to student deaths, particularly focusing on the intersection of gender, mental health, and healthcare disparities.
Mental Health and Suicidality in Adolescents with Gender Dysphoria
Adolescent gender dysphoria is an increasingly prevalent concern, often intertwined with other psychiatric conditions, including suicidal ideation and attempts. Studies indicate a significant association between gender dysphoria and mental health challenges. A survey among high school students revealed that 1.2-2.7% considered themselves transgender or uncertain of their gender. Furthermore, reports suggest a rising number of adolescents seeking specialized clinical services for gender identity treatment.
A 2017 chart review from a transgender clinic in Cincinnati highlighted that 58% of youth aged 12-22 with gender dysphoria had another psychiatric diagnosis, and 30.3% reported at least one suicide attempt. Similar studies corroborate these findings, with attempted suicide rates ranging from 26% to 31% among transgender or gender dysphoric adolescents. Emerging research has also shed light on specific aspects of body dissatisfaction as independent risk factors for self-harm within this population.
Case Study: Adolescent with Gender Dysphoria and Suicidal Ideation
A 14-year-old birth-assigned female transitioning to male presented to the emergency department (ED) with suicidal ideation. The patient had experienced depressed mood, body dysmorphia, and gender dysphoria since the age of 10. Prior to presentation, the patient had established care with outpatient psychiatry and psychology and initiated gender-affirming testosterone therapy, which was discontinued after 30 days due to uncertainty about wanting to be male.
On the day of presentation, the patient reported persistent depression, social isolation, worthlessness, and suicidal ideation, associated with body dysmorphia, gender uncertainty, and the prior process of hormone therapy. The patient expressed dissatisfaction with height, weight, and appearance, verbalizing feelings of inadequacy and self-hatred. Despite outpatient treatment and a supportive family, the patient continued to experience intermittent suicidal ideation and frustration with appearance and situation.
Read also: The Death of Emily Gold
This case underscores the psychiatric complexity of gender dysphoria and the importance of addressing body dissatisfaction and gender uncertainty in treatment. Studies have shown a significant correlation between suicidality and weight-related body dissatisfaction among transgender youth.
Considerations for Hormone Therapy
The case also raises questions about the timing of gender-affirming hormone therapy. Treatment guidelines from The Endocrine Society and World Professional Association for Transgender recommend puberty suppression (GnRH) as a reversible first step prior to gender-affirming hormone therapy, which is typically not initiated until age 16. While the decision to forgo pubertal delay in this patient may have been influenced by distress attributed to his young appearance relative to peers, gender-affirming therapy seemed to be associated with increased sadness, confusion, and frustration in this particular case.
Longitudinal studies have demonstrated improvement in psychological measures after gender suppression, cross-sex therapy at 16, and gender-affirming therapy in adulthood, suggesting the importance of following established treatment guidelines.
Importance of Collaborative Care
Gender dysphoric patients are at significant risk for psychiatric comorbidities and suicidal ideation and attempts. Primary care providers must be aware of and diligently evaluate these risks, regardless of treatment status. A collaborative, multi-disciplinary approach can help care for this vulnerable population and avoid tragic outcomes.
Disparities in Healthcare and Medical Research
Historically, medical research has often overlooked the unique biological and physiological differences between men and women, leading to disparities in healthcare outcomes. Women have been underrepresented in research, contributing to a lack of understanding of how diseases manifest and how treatments affect them differently than men.
Read also: UT Austin student death: Full details
Underrepresentation of Women in Medical Research
Despite comprising nearly half the global population, women have been historically considered "atypical" in medical research, with men's bodies serving as the "norm." This underrepresentation has contributed to healthcare disparities, as biological sex can influence physiological, metabolic, hormonal, and cellular differences that impact disease presentation and the effectiveness of pharmaceuticals and medical devices.
Failure to include a broad sampling of women in studies has resulted in adverse effects from medications occurring at twice the rate in women compared to men. For example, a 2013 study found that women with metal hip replacements were 29% more likely than men to experience implant failure, potentially due to anatomical differences and inadequate testing in women.
Recognition of Sex Differences in Heart Disease
Heart disease, the leading cause of death in the United States for both men and women, was not recognized as presenting differently in women until the American Heart Association published a Guide to Preventive Cardiology for Women in 1999. This late recognition highlights the historical lack of attention to sex differences in medical research and clinical practice.
Historical Exclusion of Women from Clinical Trials
Progress in researching drugs and medical devices in women was further hampered in 1977 when the Food and Drug Administration (FDA) created a policy to exclude women of reproductive potential from Phase 1 and 2 clinical trials unless they had a life-threatening condition. This policy was a reaction to the thalidomide tragedy, in which a drug taken by pregnant women for morning sickness caused severe birth defects in their babies. The policy was revisited nearly a decade later, in 1986.
The Need for Real-World Data
Even with policy changes aimed at increasing the inclusion of women in medical research, disparities persist, particularly for women of color. A 2022 study by researchers at Harvard Medical School highlighted the need for better access to real-world data to improve understanding and treatment of diseases in diverse populations.
Read also: Hazing and Accountability
Progress and Future Directions
Despite the challenges, there has been progress in increasing the inclusion of women in medical research. In 2016, the National Institutes of Health (NIH) instituted a policy requiring researchers with NIH funding to collect data on biological sex differences in preclinical research and animal testing, analyze the data, and report on differences in the findings.
However, there is still a lack of accountability when researchers fail to enroll a sufficient percentage of women in their clinical trials. Furthermore, medical education needs to incorporate more information on sex differences in all organ systems to ensure that healthcare professionals are equipped to provide equitable care.
tags: #ANU #student #death #statistics #causes
